Literature DB >> 21486050

Characterizing the structural behavior of selected Aβ-42 monomers with different solubilities.

Camilo Velez-Vega1, Fernando A Escobedo.   

Abstract

The conformational behavior of the wild-type amyloid β-42 (Aβ-42) monomer and two of its mutants was explored via all-atom replica exchange molecular dynamics simulations in explicit solvent, to identify structural features that may promote or deter early-stage oligomerization. The markers used for this purpose indicate that while the three peptides are relatively flexible they have distinct preferential structures and degree of rigidity. In particular, we found that one mutant that remains in the monomeric state in experiments displays a characteristic N-terminal structure that significantly enhances its rigidity. This finding is consistent with various studies that have detected a reduction in oligomerization frequency and Aβ-related toxicity upon sequence-specific antibody or ligand binding to the N-terminal tail of wild-type monomers, likely leading to the stabilization of this region. In general, our results highlight a potential role of the N-terminal segment on Aβ oligomerization and give insights into specific interactions that may be responsible for promoting the pronounced structural changes observed upon introducing point mutations on the wild-type Aβ-42 peptide.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21486050     DOI: 10.1021/jp1086575

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  14 in total

1.  Investigating how peptide length and a pathogenic mutation modify the structural ensemble of amyloid beta monomer.

Authors:  Yu-Shan Lin; Gregory R Bowman; Kyle A Beauchamp; Vijay S Pande
Journal:  Biophys J       Date:  2012-01-18       Impact factor: 4.033

2.  Mechanical resistance in unstructured proteins.

Authors:  Sigurður Ægir Jónsson; Simon Mitternacht; Anders Irbäck
Journal:  Biophys J       Date:  2013-06-18       Impact factor: 4.033

3.  Comparative studies of disordered proteins with similar sequences: application to Aβ40 and Aβ42.

Authors:  Charles K Fisher; Orly Ullman; Collin M Stultz
Journal:  Biophys J       Date:  2013-04-02       Impact factor: 4.033

Review 4.  Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.

Authors:  Orkid Coskuner-Weber; Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

5.  Arginine and disordered amyloid-β peptide structures: molecular level insights into the toxicity in Alzheimer's disease.

Authors:  Orkid Coskuner; Olivia Wise-Scira
Journal:  ACS Chem Neurosci       Date:  2013-10-08       Impact factor: 4.418

6.  Divalent copper ion bound amyloid-β(40) and amyloid-β(42) alloforms are less preferred than divalent zinc ion bound amyloid-β(40) and amyloid-β(42) alloforms.

Authors:  Orkid Coskuner
Journal:  J Biol Inorg Chem       Date:  2016-09-22       Impact factor: 3.358

7.  Discrete molecular dynamics study of oligomer formation by N-terminally truncated amyloid β-protein.

Authors:  Derya Meral; Brigita Urbanc
Journal:  J Mol Biol       Date:  2013-03-13       Impact factor: 5.469

8.  Effects of familial mutations on the monomer structure of Aβ₄₂.

Authors:  Yu-Shan Lin; Vijay S Pande
Journal:  Biophys J       Date:  2012-12-18       Impact factor: 4.033

Review 9.  The role of molecular simulations in the development of inhibitors of amyloid β-peptide aggregation for the treatment of Alzheimer's disease.

Authors:  Justin A Lemkul; David R Bevan
Journal:  ACS Chem Neurosci       Date:  2012-08-27       Impact factor: 4.418

10.  Dimer formation enhances structural differences between amyloid β-protein (1-40) and (1-42): an explicit-solvent molecular dynamics study.

Authors:  Bogdan Barz; Brigita Urbanc
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.